SYDNEY, March 5, 2026, 16:57 AEDT
- CSL bought back 59,751 shares on March 4, taking total repurchases to 4.03 million shares
- The company has paid about A$739 million so far under its on-market buyback
- CSL also disclosed 39,627 shares were issued after employee performance rights were exercised
CSL Ltd has lifted the pace of its on-market share buyback, purchasing 59,751 shares on Wednesday for A$8.57 million, an exchange filing showed. The company has now repurchased 4.03 million shares for about A$739 million under a program it has capped at up to US$750 million. 1
The steady buying matters because CSL is still trying to steady investors after a first-half profit slide and abrupt leadership change last month, while promising a sharper second-half performance. It expanded the buyback at the same time it reaffirmed full-year guidance. 2
The board has been under pressure to show it can pull the right levers quickly. “Possibly a salvage mission,” David Tuckwell, chief investment officer at ETF Shares, said at the time, referring to the decision to install company veteran Gordon Naylor as interim chief executive. 3
CSL paid between A$142.43 and A$145.18 a share for Wednesday’s stock, according to the filing. The buyback is being run through UBS Securities Australia and is scheduled to run until June 30. 1
The company also filed a separate notice showing it issued or transferred 39,627 ordinary shares on March 2 after employee “rights” were converted, including 2,212 shares tied to key management personnel Andrew Schmeltz. The shares were issued for nil consideration under CSL’s performance rights plan, the filing showed.
Performance rights are share awards that vest if conditions are met; once exercised, they can increase the share count. The same notice put CSL’s quoted ordinary shares on issue at 485.15 million and unquoted “rights” at 2.61 million.
CSL, one of Australia’s biggest listed companies, makes plasma-derived medicines, vaccines and iron deficiency and kidney drugs. Its plasma unit, CSL Behring, is the main earner.
But the buyback does not fix the operational work ahead. CSL’s own warning has been that Seqirus earnings fade in the second half because flu vaccines are seasonal, while generic competition is squeezing Vifor, leaving Behring to carry most of the turnaround — and Citi has said that leaves little margin for error. 2
CSL’s next near-term marker is its interim dividend timetable, with shares set to trade ex-dividend on March 10 and a record date on March 11, according to the company’s financial calendar. 4
